Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FYU-981 shows potential as a novel therapy for hyperuricemia

April 3, 2013

BMN-165 treatment leads to early Phe reductions in adults with PKU

April 3, 2013

Invokana approved by the FDA for type 2 diabetes

April 2, 2013

Japanese scientists design new ACC2 inhibitors

April 2, 2013

Both primary endpoints met in pivotal study of Androxal

April 2, 2013

EMA accepts ospemifene MAA

March 28, 2013

Catabasis begins phase I trial of CAT-2003 for severe hypertriglyceridemia

March 28, 2013

iBio to advance iBioLaunch-produced recombinant C1 inhibitor to clinical development

March 28, 2013

Onglyza approved in Japan for type 2 diabetes

March 27, 2013

Shionogi receives approval for metreleptin in Japan

March 27, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...